Amplia Therapeutics Ltd
ASX:ATX
Prices of ASX stocks are not being updated. The latest ATX price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Amplia Therapeutics Ltd (ATX) under the Base Case is AUD per share.
Compared with the last price of 0.1 AUD on Oct 14, the stock appears .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What Amplia Therapeutics Does
Amplia Therapeutics is a clinical-stage drug developer focused on medicines that block focal adhesion kinase, or FAK, a protein that helps some cancers and scar-forming diseases grow and spread. Its lead drug candidate is being tested mainly in hard-to-treat cancers, especially pancreatic cancer, and the company also studies related fibrosis indications. It does not sell approved drugs today; its work is centered on research, clinical trials, and building a portfolio of potential treatments.
- Headquarters
- Australia AU
- IPO date
- Dec 23, 2013
Earnings Waterfall
Amplia Therapeutics Ltd
What is the Intrinsic Value of one ATX stock?
The intrinsic value for Amplia Therapeutics Ltd (ATX) under the Base Case is AUD.
Is ATX stock undervalued or overvalued?
Compared with the last price of 0.1 AUD on Oct 14, the stock appears .
